DE69920002D1 - Konjugate aus polyole und beta-interferon - Google Patents

Konjugate aus polyole und beta-interferon

Info

Publication number
DE69920002D1
DE69920002D1 DE69920002T DE69920002T DE69920002D1 DE 69920002 D1 DE69920002 D1 DE 69920002D1 DE 69920002 T DE69920002 T DE 69920002T DE 69920002 T DE69920002 T DE 69920002T DE 69920002 D1 DE69920002 D1 DE 69920002D1
Authority
DE
Germany
Prior art keywords
conjugates
polyols
beta interferon
interferon
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920002T
Other languages
English (en)
Other versions
DE69920002T2 (de
Inventor
Tayar Nabil El
J Roberts
Milton Harris
Wayne Sawlivich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Application granted granted Critical
Publication of DE69920002D1 publication Critical patent/DE69920002D1/de
Publication of DE69920002T2 publication Critical patent/DE69920002T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
DE69920002T 1998-04-28 1999-04-28 Konjugate aus polyole und beta-interferon Expired - Lifetime DE69920002T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28
US83339P 1998-04-28
PCT/US1999/009161 WO1999055377A2 (en) 1998-04-28 1999-04-28 Polyol-ifn-beta conjugates

Publications (2)

Publication Number Publication Date
DE69920002D1 true DE69920002D1 (de) 2004-10-14
DE69920002T2 DE69920002T2 (de) 2005-09-22

Family

ID=22177687

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69920002T Expired - Lifetime DE69920002T2 (de) 1998-04-28 1999-04-28 Konjugate aus polyole und beta-interferon
DE69936409T Expired - Lifetime DE69936409T2 (de) 1998-04-28 1999-04-28 Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69936409T Expired - Lifetime DE69936409T2 (de) 1998-04-28 1999-04-28 Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide

Country Status (31)

Country Link
US (3) US6638500B1 (de)
EP (2) EP1421956B1 (de)
JP (2) JP4574007B2 (de)
KR (1) KR100622796B1 (de)
CN (2) CN1187094C (de)
AR (1) AR020070A1 (de)
AT (2) ATE275422T1 (de)
AU (1) AU762621B2 (de)
BG (2) BG64694B1 (de)
BR (1) BR9910023A (de)
CA (2) CA2565375A1 (de)
CY (1) CY1108022T1 (de)
CZ (2) CZ298579B6 (de)
DE (2) DE69920002T2 (de)
DK (2) DK1075281T3 (de)
EA (2) EA005495B1 (de)
EE (1) EE05214B1 (de)
ES (2) ES2224649T3 (de)
HK (2) HK1038194A1 (de)
HU (1) HUP0300548A3 (de)
IL (1) IL139286A (de)
NO (2) NO329749B1 (de)
NZ (1) NZ507456A (de)
PL (2) PL193352B1 (de)
PT (2) PT1421956E (de)
SI (2) SI1421956T1 (de)
SK (2) SK286217B6 (de)
TR (2) TR200003161T2 (de)
TW (2) TWI266800B (de)
UA (2) UA66857C2 (de)
WO (1) WO1999055377A2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
CN1329082C (zh) * 1998-10-16 2007-08-01 拜奥根Idec马萨诸塞公司 干扰素－β－1a的聚合物缀合物及其使用
TR200101087T2 (tr) 1998-10-16 2001-09-21 Biogen, Inc. İnterferon beta-füzyon proteinleri ve kullanımları
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
KR100642955B1 (ko) * 1999-04-23 2006-11-10 알자 코포레이션 방출성 결합 및 그를 함유하는 조성물
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
TR200101086A3 (de) * 1999-10-15 2001-08-21
EP1270642B1 (de) * 1999-12-24 2011-08-31 Kyowa Hakko Kirin Co., Ltd. Verzweigte polyalkylenglykole
WO2001051510A2 (en) 2000-01-10 2001-07-19 Maxygen Holdings Ltd G-csf conjugates
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
ATE471956T1 (de) 2001-01-30 2010-07-15 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
EP1234583A1 (de) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-Konjugate des HGF-NK4
YU48703A (sh) 2001-02-27 2006-05-25 Maxygen Aps Novi interferonu beta-slični molekuli
ATE468862T1 (de) 2001-07-11 2010-06-15 Maxygen Inc G-csf konjugate
KR100964411B1 (ko) 2002-01-18 2010-06-15 바이오겐 아이덱 엠에이 인코포레이티드 생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US9125880B2 (en) * 2002-12-26 2015-09-08 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
GEP20084487B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
WO2004083361A2 (en) 2003-03-20 2004-09-30 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2633866A3 (de) 2003-10-17 2013-12-18 Novo Nordisk A/S Kombinationstherapie
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
US8778880B2 (en) * 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
EP1586334A1 (de) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF Konjugate mit PEG
CN1984673A (zh) 2004-05-17 2007-06-20 阿雷斯贸易股份有限公司 干扰素水凝胶制剂
EA010979B1 (ru) 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
BRPI0510527A (pt) 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
JP5243041B2 (ja) * 2004-12-21 2013-07-24 ネクター セラピューティックス 安定化ポリマーチオール試薬
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
SG161210A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
AU2005322019B2 (en) 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
CN101257926A (zh) * 2005-08-04 2008-09-03 尼克塔治疗亚拉巴马公司 G-csf部分与聚合物的轭合物
US20080219952A1 (en) 2005-08-26 2008-09-11 Ares Trading S.A. Process For the Preparation of Glycosylated Interferon Beta
WO2007025991A2 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
CA2653748A1 (en) * 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
JP2009537605A (ja) 2006-05-24 2009-10-29 メルク セローノ ソシエテ アノニム 多発性硬化症を治療するためのクラドリビン・レジメン
EP2029738A2 (de) 2006-05-24 2009-03-04 Novo Nordisk Health Care AG Faktor-ix-analoge mit verlängerter in-vivo-halbwertszeit
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
AU2008340058A1 (en) 2007-12-20 2009-07-02 Merck Serono S.A. PEG-interferon-beta formulations
NZ620606A (en) 2008-02-08 2015-08-28 Ambrx Inc Modified leptin polypeptides and their uses
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
US20130040888A1 (en) 2010-02-16 2013-02-14 Novo Nordisk A/S Factor VIII Molecules With Reduced VWF Binding
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
CN102971006A (zh) 2010-07-15 2013-03-13 诺沃—诺迪斯克有限公司 稳定的因子viii变体
AU2011303916A1 (en) 2010-09-15 2013-03-21 Novo Nordisk A/S Factor VIII variants having a decreased cellular uptake
EP3395356B1 (de) * 2011-02-18 2021-05-19 Stemdr Inc. Zusammensetzung mit einem induktor der sirt1-expression zur vorbeugung oder behandlung von sepsis oder septischen schocks
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
EP2762489B1 (de) * 2011-10-01 2018-03-28 Glytech, Inc. Glykosyliertes polypeptid und pharmazeutische zusammensetzung damit
KR102057356B1 (ko) 2012-02-27 2019-12-18 아뮤닉스 파마슈티컬스, 인크. Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법
CN104136038A (zh) 2012-02-29 2014-11-05 东丽株式会社 体腔积液抑制剂
US10053499B2 (en) 2013-03-29 2018-08-21 Glytech, Inc. Polypeptide having sialylated sugar chains attached thereto
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
MX2017002140A (es) 2014-08-19 2017-08-21 Biogen Ma Inc Metodo de pegilacion.
ES2903448T3 (es) 2015-05-01 2022-04-01 Allysta Pharmaceuticals Inc Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares
MX2017016674A (es) * 2015-06-19 2018-08-01 Eisai R&D Man Co Ltd Inmunoglobulinas conjugadas en cys80.
US11324811B2 (en) * 2017-04-17 2022-05-10 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
EP3919128A4 (de) 2019-01-28 2023-01-11 Toray Industries, Inc. Polyethylenglykolmodifizierter körper für hepatorytenwachstumsfaktor oder aktives fragment davon
BR112021012880A2 (pt) 2019-01-28 2021-11-16 Toray Ind Inc Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5711944A (en) 1993-11-10 1998-01-27 Enzon, Inc. Interferon polymer conjugates
CZ288926B6 (cs) * 1994-03-31 2001-09-12 Amgen Inc. MGDF derivát, způsob jeho výroby a farmaceutický prostředek s jeho obsahem
CA2190502A1 (en) * 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
AU5773798A (en) * 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
SK286654B6 (sk) 2009-03-05
KR100622796B1 (ko) 2006-09-13
SI1075281T1 (en) 2005-02-28
CN1302209A (zh) 2001-07-04
CZ20003995A3 (en) 2001-06-13
JP4574007B2 (ja) 2010-11-04
WO1999055377A3 (en) 1999-12-29
ES2224649T3 (es) 2005-03-01
CN1637020A (zh) 2005-07-13
NO329749B1 (no) 2010-12-13
EA003789B1 (ru) 2003-10-30
EP1421956B1 (de) 2007-06-27
CN1187094C (zh) 2005-02-02
EE200000614A (et) 2002-04-15
BG109291A (en) 2006-04-28
DK1421956T3 (da) 2007-10-01
US6638500B1 (en) 2003-10-28
WO1999055377A9 (en) 2000-03-02
AU3767499A (en) 1999-11-16
DE69920002T2 (de) 2005-09-22
ATE275422T1 (de) 2004-09-15
IL139286A0 (en) 2001-11-25
HUP0300548A3 (en) 2005-07-28
CN100335503C (zh) 2007-09-05
US7700314B2 (en) 2010-04-20
DK1075281T3 (da) 2005-01-03
DE69936409T2 (de) 2008-04-17
NZ507456A (en) 2003-10-31
BG104871A (en) 2001-07-31
KR20010071158A (ko) 2001-07-28
NO20005337L (no) 2000-12-28
NO20100324L (no) 2000-12-28
EA200001111A1 (ru) 2001-04-23
UA66857C2 (uk) 2004-06-15
PT1075281E (pt) 2004-11-30
AR020070A1 (es) 2002-04-10
AU762621B2 (en) 2003-07-03
ES2285286T3 (es) 2007-11-16
PT1421956E (pt) 2007-07-13
EA200300382A1 (ru) 2005-02-24
SK16222000A3 (sk) 2001-04-09
NO332224B1 (no) 2012-07-30
CA2565375A1 (en) 1999-11-04
BG64694B1 (bg) 2005-12-30
PL196533B1 (pl) 2008-01-31
CZ298579B6 (cs) 2007-11-14
WO1999055377A2 (en) 1999-11-04
EP1075281A2 (de) 2001-02-14
TR200101751T2 (tr) 2002-05-21
US20040043002A1 (en) 2004-03-04
EA005495B1 (ru) 2005-02-24
US7357925B2 (en) 2008-04-15
CY1108022T1 (el) 2013-09-04
HK1076115A1 (en) 2006-01-06
HK1038194A1 (en) 2002-03-08
US20070141620A1 (en) 2007-06-21
CA2330451A1 (en) 1999-11-04
EP1421956A1 (de) 2004-05-26
DE69936409D1 (de) 2007-08-09
BR9910023A (pt) 2000-12-26
NO20005337D0 (no) 2000-10-23
ATE365563T1 (de) 2007-07-15
TWI266800B (en) 2006-11-21
JP2010184929A (ja) 2010-08-26
TR200003161T2 (tr) 2001-01-22
PL193352B1 (pl) 2007-02-28
HUP0300548A2 (hu) 2003-06-28
PL344490A1 (en) 2001-11-05
SK286217B6 (sk) 2008-05-06
UA79430C2 (en) 2007-06-25
IL139286A (en) 2005-12-18
BG65046B1 (bg) 2007-01-31
EE05214B1 (et) 2009-10-15
EP1075281B1 (de) 2004-09-08
TWI232882B (en) 2005-05-21
JP2002512983A (ja) 2002-05-08
CZ298597B6 (cs) 2007-11-21
SI1421956T1 (sl) 2007-10-31

Similar Documents

Publication Publication Date Title
DE69920002D1 (de) Konjugate aus polyole und beta-interferon
ATE480590T1 (de) Rheologieveränderte thermoplastische elastomerzusammensetzungen und gegenstände daraus
NO995263D0 (no) Konjugater av polyetylenglykol og interferon-<alfa> for terapi av infeksjoner
KR970705598A (ko) 소결 가능한 반결정성 분체 및 이를 사용하여 형성한 물품(Sinterable semicrystalline powder and article formed therewith)
DK1035830T3 (da) Kosmetiske sammensætninger med dibenzylidensorbitol og funktionaliserede siliconer
DE69918233D1 (de) Polymilchsäure zusammensetzung und daraus hergestellter film
DE10080582T1 (de) Harzzusammensetzung und Transport-Montagegestell
DE69826708D1 (de) Zusammenstellungen aus trägern und reporterkügelchen
DE69915066D1 (de) Biozide zusammensetzung und deren verwendung
DE29809933U1 (de) Anatomische Matratze aus elastischem Material
FI981506A (fi) Elastomeerikompositio ja sen valmistusmenetelmä
DE69905644D1 (de) Fördermatte und Fördervorrichtung
DK1037658T3 (da) IFNAR2/IFN-kompleks
BR9509650A (pt) Material superabsorvente e utilização do mesmo
DE69122749D1 (de) Kombination aus extremitätenlaken und beinhalterung
DE69127962D1 (de) Leitfähige Silikongummizusammensetzung und leitfähiger Silikongummi
DE69917071D1 (de) Klebstoffzusammensetzungen und klebebahnen
ATE250339T1 (de) Dormanz-brechende zusammenstezung und deren verwendung
DK0869132T3 (da) Steroidforbindelser med svangerskabsforebyggende virkning og anti-osteoporose-virkning
DE59906154D1 (de) Antistatische und peroxidstabile Formmassen
ATE282015T1 (de) Rheologieänderung und rheologiemodifiziermittel
DE69522196T2 (de) Pufferschaltung und Vorspannungsschaltung
DE59807961D1 (de) Sensorenanordnung bestehend aus sensor und auswerteschaltung
DE69930017D1 (de) Glaskeramischer körper
DE69924321D1 (de) Medizinischer Gegenstand aus Aluminiumoxydkeramik

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LABORATOIRES SERONO S.A., COINSINS, VAUD, CH